
<ns0:uwmetadata xmlns:ns0="http://phaidra.univie.ac.at/XML/metadata/V1.0" xmlns:ns1="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0" xmlns:ns10="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0" xmlns:ns11="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0/entity" xmlns:ns12="http://phaidra.univie.ac.at/XML/metadata/digitalbook/V1.0" xmlns:ns13="http://phaidra.univie.ac.at/XML/metadata/etheses/V1.0" xmlns:ns2="http://phaidra.univie.ac.at/XML/metadata/extended/V1.0" xmlns:ns3="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/entity" xmlns:ns4="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/requirement" xmlns:ns5="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/educational" xmlns:ns6="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/annotation" xmlns:ns7="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/classification" xmlns:ns8="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/organization" xmlns:ns9="http://phaidra.univie.ac.at/XML/metadata/histkult/V1.0">
  <ns1:general>
    <ns1:identifier>o:9739</ns1:identifier>
    <ns1:title language="sr">C-reaktivni protein određen visokosenzitivnom metodom i lipidni biomarkeri u predikciji razvoja i progresije periferne arterijske bolesti kod pacijenata sa tipom 2 dijabetesa </ns1:title>
    <ns2:subtitle language="sr">doktorska disertacija</ns2:subtitle>
    <ns2:alt_title language="en">C-reaktive protein determined by highsensitivitz method and biomarkers in prediction of development and progression of peripheral arterial disease in patients with type 2 diabetes : doctoral dissertation</ns2:alt_title>
    <ns1:language>sr</ns1:language>
    <ns1:description language="sr">Uvod: Predhodne studije su ukazale na visoko senzitivni C - reaktivni protein (hs-CRP) kao
faktor rizika za perifernu arterijsku bolest (PAB) u dijabetesu. Stidja je imala za cilj da se
proceni mogući prediktivni značaj hs-CRP i lipidnih biomarkera (holesterol, LDL-holesterol,
HDL-holesterol, trigliceridi, Apo A1, Apo B i Lp (a)) u razvoju i progresiji PAD u pacijenata sa
tipom 2 dijabetesa (T2D).
Metode: U studiju je uključeno 80 pacijenata sa prethodnom dijagnozom T2D, starosti 45-70
godina, podeljenih u grupu A (T2D pacijenti sa PAB; n=38) i grupu B (T2D pacijenti bez PAB;
n=42). Posle 5 godina, pacijenti su podeljeni u podgrupe u zavisnosti od prisustva nove pojave
PAB ili progresije prethodno postojeće PAB. Pedo-brahijalni indeks (PBI) je korišćen za
dijagnozu PAB a hs-CRP je odredjen nefelometrijski
Rezultati: Našli smo značajno viši nivo hs-CRP u grupi A u odnosu na grupu B, ali samo na
početku studije. U okviru grupe A, pacijenti sa kasnijom progresijom PAD (podgrupa A1) imali
su najviši nivo hs-CRP na početku, mada bez značajne razlike u odnosu na podgrupu A2.
Suprotno, nivo hs-CRP bio je značajno viši u podgrupi B1 u poredjenju sa subgrupom B2 i na
početku i na kraju ispitivanja. Od svih ispitivanih metaboličkih parametara-lipidnih biomarkera,
hs-CRP je bio jedini nezavisni prediktor progresije PAD (OR=0.456, 95%CI=0.267-0.7815,
p=0.004). Nivo hs-CRP od 2.5 mg/L je utvrdjen kao “cut-off” vrednost (specifičnost 75% i
senzitivnost 73.3%) sa relativnim rizikom za PAD od 2.93 (95% CI 1.351-6.3629).
Zaključak: Naša studija je pokazala da se hs-CRP može koristiti kao pouzdan prediktor
progresije PAB u pacijenata sa T2D.
</ns1:description>
    <ns1:description language="en">Background: Previous studies indicated high sensitivity C-reactive protein (hs-CRP) as a risk
factor for the peripheral arterial disease (PAD) in diabetes. This study aimed to evaluate possible
predictive significance of hs-CRP and lipid biomarkers (total cholesterol, LDL-cholesterol,
HDL-cholesterol, triglycerides, Apo A1 and Apo B, Lp (a)) for development and progression of
PAD in patients with type 2 diabetes (T2D).
Methods: The study included 80 patients previously diagnosed with T2D, aged 45-70 years,
divided into group A (T2D patients with PAD; n=38) and group B (T2D patients without PAD;
n=42). After five years, all the patients were reexamined and divided into subgroups depending
on de novo development of PAD or progression of previously diagnosed PAD. Ankle-Brachial
Index (ABI) measurement was used for PAD diagnosis and hs-CRP was determined by
nephelometry.
Results: We found significantly higher hs-CRP level in group A compared to group B, but only
at baseline. Among patients in group A, those with later progression of PAD (subgroups A1) had
highest level of hs-CRP at baseline, although not significantly different compared to subgroup
A2. In contrast, hs-CRP level was significantly higher in subgroup B1 in comparison to subgroup
B2 at both first and second exam. Of all investigated metabolic parameters-lipid biomarkers, hs-
CRP was the only independent predictor of progression of PAD (OR=0.456, 95%CI=0.267-
0.7815, p=0.004). The cut-off point for hs-CRP was 2.5 mg/L (specificity 75% and sensitivity
73.3%) with the relative risk for PAD of 2.93 (95% CI 1.351-6.3629).
Conclusions: Our study implies that hs-CRP can be used as a reliable predictor for progression
of PAD in patients with T2D.</ns1:description>
    <ns1:description language="sr">MEDICINA - INTERNA MEDICINA, ENDOKRINOLOGIJA / MEDICINE
- INTERNAL MEDICINE,ENDOCTINOLOGY
Datum odbrane : 25.12..2014</ns1:description>
    <ns1:keyword language="sr">Pedo-brahijalni indeks, C - reaktivni protein, lipidni biomarkeri, perifernaarterijska bolest, tip 2 dijabetesa</ns1:keyword>
    <ns1:keyword language="en">Ankle-Brachial Index, C - reactive protein, lipid biomarkers, peripheral arterialdisease, type 2 diabetes</ns1:keyword>
    <ns1:keyword language="sr">616.379</ns1:keyword>
    <ns2:irdata>yes</ns2:irdata>
    <ns2:identifiers>
      <ns2:identifier>46758415</ns2:identifier>
    </ns2:identifiers>
    <ns2:identifiers>
      <ns2:resource>91552101</ns2:resource>
      <ns2:identifier>1992</ns2:identifier>
    </ns2:identifiers>
    <ns2:identifiers>
      <ns2:resource>91552100</ns2:resource>
      <ns2:identifier>46758415</ns2:identifier>
    </ns2:identifiers>
  </ns1:general>
  <ns1:lifecycle>
    <ns1:upload_date>2015-09-17T12:16:36.053Z</ns1:upload_date>
    <ns1:status>45</ns1:status>
    <ns2:peer_reviewed>no</ns2:peer_reviewed>
    <ns1:contribute seq="0">
      <ns1:role>46</ns1:role>
      <ns1:ext_role>mentor</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Ljiljana J., 1964- </ns3:firstname>
        <ns3:lastname>Popović</ns3:lastname>
      </ns1:entity>
      <ns1:date>2014</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="1">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>mentor</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Miroslava, 1946- </ns3:firstname>
        <ns3:lastname>Zamaklar</ns3:lastname>
      </ns1:entity>
      <ns1:date>2014</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="2">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Katarina, 1962- </ns3:firstname>
        <ns3:lastname>Lalić</ns3:lastname>
      </ns1:entity>
      <ns1:date>2014</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="3">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Aleksandra, 1966- </ns3:firstname>
        <ns3:lastname>Jotić</ns3:lastname>
      </ns1:entity>
      <ns1:date>2014</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="4">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Georgina</ns3:firstname>
        <ns3:lastname>Pudar</ns3:lastname>
      </ns1:entity>
      <ns1:date>2014</ns1:date>
    </ns1:contribute>
  </ns1:lifecycle>
  <ns1:technical>
    <ns1:format>PDF/A (80 listova)</ns1:format>
    <ns1:size>2536994</ns1:size>
    <ns1:location>http://phaidrabg.bg.ac.rs/o:9739</ns1:location>
  </ns1:technical>
  <ns1:rights>
    <ns1:cost>no</ns1:cost>
    <ns1:copyright>yes</ns1:copyright>
    <ns1:license>3</ns1:license>
  </ns1:rights>
  <ns1:annotation>
    <ns6:annotations>
      <ns6:date>2015-09-17T12:16:36.320Z</ns6:date>
    </ns6:annotations>
  </ns1:annotation>
  <ns1:classification>
    <ns1:purpose>70</ns1:purpose>
    <ns7:taxonpath>
      <ns7:source>11</ns7:source>
      <ns7:taxon seq="0">1066950</ns7:taxon>
      <ns7:taxon seq="1">1066999</ns7:taxon>
    </ns7:taxonpath>
    <ns7:description language="sr">MEDICINA - INTERNA MEDICINA, ENDOKRINOLOGIJA / </ns7:description>
    <ns7:keyword language="sr" seq="0">Pedo-brahijalni indeks, C - reaktivni protein, lipidni biomarkeri, perifernaarterijska bolest, tip 2 dijabetesa</ns7:keyword>
    <ns7:keyword language="en" seq="1">Ankle-Brachial Index, C - reactive protein, lipid biomarkers, peripheral arterialdisease, type 2 diabetes</ns7:keyword>
    <ns7:keyword language="sr" seq="2">616.379</ns7:keyword>
  </ns1:classification>
  <ns1:organization>
    <ns8:hoschtyp>1738</ns8:hoschtyp>
    <ns8:orgassignment>
      <ns8:faculty>11A32</ns8:faculty>
    </ns8:orgassignment>
  </ns1:organization>
  <ns12:digitalbook>
    <ns12:releaseyear>2014</ns12:releaseyear>
  </ns12:digitalbook>
</ns0:uwmetadata>
